Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

George Bigelow

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Activities & Behaviors

Psychomotor Performance

Anatomy

Pupil

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
100
Stitzer, Maxine
48
Strain, Eric
44
Liebson, Ira
40
Preston, Kenzie
39
Walsh, Sharon
33
Griffiths, Roland
22
McCaul, Mary
19
Johnson, Rolley
19
Brooner, Robert
15
Silverman, Kenneth
10
Svikis, Dace
8
Schmidt, Chester
8
Eissenberg, Thomas
6
Donny, Eric
6
Ford, Daniel

Sign-in to see all Coauthors

Publications

TOP 3
Tompkins D Andrew; Bigelow George E; Harrison Joseph A; Johnson Rolley E; Fudala Paul J; Strain Eric C
Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument.
Walsh Sharon L; Stoops William W; Moody David E; Lin Shen-Nan; Bigelow George E
Repeated dosing with oral cocaine in humans: assessment of direct effects, withdrawal, and pharmacokinetics.
Rogers Randall E; Higgins Stephen T; Silverman Kenneth; Thomas Colleen S; Badger Gary J; Bigelow George; Stitzer Maxine
Abstinence-contingent reinforcement and engagement in non-drug-related activities among illicit drug abusers.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of George Bigelow (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Tompkins D Andrew; Bigelow George E; Harrison Joseph A; Johnson Rolley E; Fudala Paul J; Strain Eric C
Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument.
Drug and alcohol dependence 2009;105(1-2):154-9.
2009: Walsh Sharon L; Stoops William W; Moody David E; Lin Shen-Nan; Bigelow George E
Repeated dosing with oral cocaine in humans: assessment of direct effects, withdrawal, and pharmacokinetics.
Experimental and clinical psychopharmacology 2009;17(4):205-16.
2008: Rogers Randall E; Higgins Stephen T; Silverman Kenneth; Thomas Colleen S; Badger Gary J; Bigelow George; Stitzer Maxine
Abstinence-contingent reinforcement and engagement in non-drug-related activities among illicit drug abusers.
Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors 2008;22(4):544-50.
2008: O'Toole Thomas P; Pollini Robin A; Ford Daniel E; Bigelow George
The health encounter as a treatable moment for homeless substance-using adults: the role of homelessness, health seeking behavior, readiness for behavior change and motivation for treatment.
Addictive behaviors 2008;33(9):1239-43.
2008: Cao Ying-Jun; Smith Patrick F; Wire Mary Beth; Lou Yu; Lancaster Charles T; Causon Roger C; Bigelow George E; Martinez Elizabeth; Fuchs Edward J; Radebaugh Christine; McCabe Sarah; Hendrix Craig W
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Pharmacotherapy 2008;28(7):863-74.
2008: Lanier Ryan K; Umbricht Annie; Harrison Joseph A; Nuwayser Elie S; Bigelow George E
Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation.
Psychopharmacology 2008;198(2):149-58.
2008: Walsh S L; Chausmer A E; Strain E C; Bigelow G E
Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade.
Psychopharmacology 2008;196(1):143-55.
2007: Wedam Erich F; Bigelow George E; Johnson Rolley E; Nuzzo Paul A; Haigney Mark C P
QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial.
Archives of internal medicine 2007;167(22):2469-75.
2007: O'Toole Thomas P; Pollini Robin A; Ford Daniel E; Bigelow George
The effect of integrated medical-substance abuse treatment during an acute illness on subsequent health services utilization.
Medical care 2007;45(11):1110-5.
2007: Lanier Ryan K; Umbricht Annie; Harrison Joseph A; Nuwayser Elie S; Bigelow George E
Evaluation of a transdermal buprenorphine formulation in opioid detoxification.
Addiction (Abingdon, England) 2007;102(10):1648-56.
2007: Lofwall Michelle R; Walsh Sharon L; Bigelow George E; Strain Eric C
Modest opioid withdrawal suppression efficacy of oral tramadol in humans.
Psychopharmacology 2007;194(3):381-93.
2007: Rosado James; Walsh Sharon L; Bigelow George E; Strain Eric C
Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
Drug and alcohol dependence 2007;90(2-3):261-9.
2007: Vandrey Ryan; Bigelow George E; Stitzer Maxine L
Contingency management in cocaine abusers: a dose-effect comparison of goods-based versus cash-based incentives.
Experimental and clinical psychopharmacology 2007;15(4):338-43.
2007: Lofwall Michelle R; Walsh Sharon L; Bigelow George E; Strain Eric C
Experimentally-induced spontaneous opiate withdrawal: relationship to cigarette craving and expired air carbon monoxide.
The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 2007;16(4):310-5.
2007: O'Toole Thomas P; Pollini Robin; Gray Paulette; Jones Theodore; Bigelow George; Ford Daniel E
Factors identifying high-frequency and low-frequency health service utilization among substance-using adults.
Journal of substance abuse treatment 2007;33(1):51-9.
2006: Correia Christopher J; Walsh Sharon L; Bigelow George E; Strain Eric C
Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
Psychopharmacology 2006;189(3):297-306.
2006: Pollini Robin A; O'Toole Thomas P; Ford Daniel; Bigelow George
Does this patient really want treatment? Factors associated with baseline and evolving readiness for change among hospitalized substance using adults interested in treatment.
Addictive behaviors 2006;31(10):1904-18.
2006: Lott David C; Strain Eric C; Brooner Robert K; Bigelow George E; Johnson Rolley E
HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone.
Journal of substance abuse treatment 2006;31(2):187-94.
2006: O'Toole Thomas P; Pollini Robin A; Ford Daniel; Bigelow George
Physical health as a motivator for substance abuse treatment among medically ill adults: is it enough to keep them in treatment?
Journal of substance abuse treatment 2006;31(2):143-50.
2006: Donny Eric C; Bigelow George E; Walsh Sharon L
Comparing the physiological and subjective effects of self-administered vs yoked cocaine in humans.
Psychopharmacology 2006;186(4):544-52.
2006: O'Toole Thomas P; Conde-Martel Alicia; Young J Hunter; Price Jennifer; Bigelow George; Ford Daniel E
Managing acutely ill substance-abusing patients in an integrated day hospital outpatient program: medical therapies, complications, and overall treatment outcomes.
Journal of general internal medicine 2006;21(6):570-6.
2006: Carroll C Patrick; Walsh Sharon L; Bigelow George E; Strain Eric C; Preston Kenzie L
Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans.
Experimental and clinical psychopharmacology 2006;14(2):109-20.
2006: Sigmon Stacey C; Moody David E; Nuwayser Elie S; Bigelow George E
An injection depot formulation of buprenorphine: extended bio-delivery and effects.
Addiction (Abingdon, England) 2006;101(3):420-32.
2005: Marsch Lisa A; Stephens Mary Ann Chutuape; Mudric Timothy; Strain Eric C; Bigelow George E; Johnson Rolley E
Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence.
Experimental and clinical psychopharmacology 2005;13(4):293-302.
2005: Donny Eric C; Brasser Susan M; Bigelow George E; Stitzer Maxine L; Walsh Sharon L
Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers.
Addiction (Abingdon, England) 2005;100(10):1496-509.
2005: Correia Christopher J; Sigmon Stacey C; Silverman Kenneth; Bigelow George; Stitzer Maxine L
A comparison of voucher-delivery schedules for the initiation of cocaine abstinence.
Experimental and clinical psychopharmacology 2005;13(3):253-8.
2005: Lofwall Michelle R; Brooner Robert K; Bigelow George E; Kindbom Kori; Strain Eric C
Characteristics of older opioid maintenance patients.
Journal of substance abuse treatment 2005;28(3):265-72.
2004: Sigmon Stacey C; Wong Conrad J; Chausmer Allison L; Liebson Ira A; Bigelow George E
Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
Addiction (Abingdon, England) 2004;99(11):1439-49.
2004: Jones Hendrée E; Johnson Rolley E; Bigelow George E; Silverman Kenneth; Mudric Tim; Strain Eric C
Safety and efficacy of L-tryptophan and behavioral incentives for treatment of cocaine dependence: a randomized clinical trial.
The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 2004;13(5):421-37.
2004: Brooner Robert K; Kidorf Michael S; King Van L; Stoller Kenneth B; Peirce Jessica M; Bigelow George E; Kolodner Ken
Behavioral contingencies improve counseling attendance in an adaptive treatment model.
Journal of substance abuse treatment 2004;27(3):223-32.
2004: Silverman Kenneth; Robles Elias; Mudric Timothy; Bigelow George E; Stitzer Maxine L
A randomized trial of long-term reinforcement of cocaine abstinence in methadone-maintained patients who inject drugs.
Journal of consulting and clinical psychology 2004;72(5):839-54.
2004: Hendrix Craig W; Wakeford John; Wire Mary Beth; Lou Yu; Bigelow George E; Martinez Elizabeth; Christopher Jared; Fuchs Edward J; Snidow Jerry W
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects.
Pharmacotherapy 2004;24(9):1110-21.
2004: Strain Eric C; Moody David E; Stoller Kenneth B; Walsh Sharon L; Bigelow George E
Relative bioavailability of different buprenorphine formulations under chronic dosing conditions.
Drug and alcohol dependence 2004;74(1):37-43.
2004: Donny Eric C; Bigelow George E; Walsh Sharon L
Assessing the initiation of cocaine self-administration in humans during abstinence: effects of dose, alternative reinforcement, and priming.
Psychopharmacology 2004;172(3):316-23.
2004: Houtsmuller Elisabeth J; Notes Lisa D; Newton Thomas; van Sluis Nicolette; Chiang Nora; Elkashef Ahmed; Bigelow George E
Transdermal selegiline and intravenous cocaine: safety and interactions.
Psychopharmacology 2004;172(1):31-40.
2004: Sobel Bai-Fang X; Sigmon Stacey C; Walsh Sharon L; Johnson Rolley E; Liebson Ira A; Nuwayser Elie S; Kerrigan James H; Bigelow George E
Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification.
Drug and alcohol dependence 2004;73(1):11-22.
2003: Correia Christopher J; Dallery Jesse; Katz Elizabeth C; Silverman Kenneth; Bigelow George; Stitzer Maxine L
Single- versus dual-drug target: effects in a brief abstinence incentive procedure.
Experimental and clinical psychopharmacology 2003;11(4):302-8.
2003: Griffiths Roland R; Bigelow George E; Ator Nancy A
Principles of initial experimental drug abuse liability assessment in humans.
Drug and alcohol dependence 2003;70(3 Suppl):S41-54.
2003: Balster Robert L; Bigelow George E
Guidelines and methodological reviews concerning drug abuse liability assessment.
Drug and alcohol dependence 2003;70(3 Suppl):S13-40.
2003: Walsh Sharon L; Strain Eric C; Bigelow George E
Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.
Addiction (Abingdon, England) 2003;98(4):427-39.
2003: Donny Eric C; Bigelow George E; Walsh Sharon L
Choosing to take cocaine in the human laboratory: effects of cocaine dose, inter-choice interval, and magnitude of alternative reinforcement.
Drug and alcohol dependence 2003;69(3):289-301.
2003: Zacny James; Bigelow George; Compton Peggy; Foley Kathleen; Iguchi Martin; Sannerud Christine
College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement.
Drug and alcohol dependence 2003;69(3):215-32.
2002: Silverman Kenneth; Svikis Dace; Wong Conrad J; Hampton Jacqueline; Stitzer Maxine L; Bigelow George E
A reinforcement-based therapeutic workplace for the treatment of drug abuse: three-year abstinence outcomes.
Experimental and clinical psychopharmacology 2002;10(3):228-40.
2002: Donny Eric C; Walsh Sharon L; Bigelow George E; Eissenberg Thomas; Stitzer Maxine L
High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans.
Psychopharmacology 2002;161(2):202-12.
2002: Katz Elizabeth C; Robles-Sotelo Elias; Correia Christopher J; Silverman Kenneth; Stitzer Maxine L; Bigelow George
The brief abstinence test: effects of continued incentive availability on cocaine abstinence.
Experimental and clinical psychopharmacology 2002;10(1):10-7.
2002: Strain Eric C; Walsh Sharon L; Bigelow George E
Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
Psychopharmacology 2002;159(2):161-6.
2002: Robles Elias; Stitzer Maxine L; Strain Eric C; Bigelow George E; Silverman Kenneth
Voucher-based reinforcement of opiate abstinence during methadone detoxification.
Drug and alcohol dependence 2002;65(2):179-89.
2001: Evans S M; Walsh S L; Levin F R; Foltin R W; Fischman M W; Bigelow G E
Effect of flupenthixol on subjective and cardiovascular responses to intravenous cocaine in humans.
Drug and alcohol dependence 2001;64(3):271-83.
2001: Lin S N; Moody D E; Bigelow G E; Foltz R L
A validated liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method for quantitation of cocaine and benzoylecgonine in human plasma.
Journal of analytical toxicology 2001;25(7):497-503.
2001: Walsh S L; Geter-Douglas B; Strain E C; Bigelow G E
Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans.
The Journal of pharmacology and experimental therapeutics 2001;299(1):147-58.
2001: Walsh S L; Strain E C; Abreu M E; Bigelow G E
Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans.
Psychopharmacology 2001;157(2):151-62.
2001: Dallery J; Silverman K; Chutuape M A; Bigelow G E; Stitzer M L
Voucher-based reinforcement of opiate plus cocaine abstinence in treatment-resistant methadone patients: effects of reinforcer magnitude.
Experimental and clinical psychopharmacology 2001;9(3):317-25.
2001: Nann-Vernotica E; Donny E C; Bigelow G E; Walsh S L
Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine.
Psychopharmacology 2001;155(4):338-47.
2001: Stoller K B; Bigelow G E; Walsh S L; Strain E C
Effects of buprenorphine/naloxone in opioid-dependent humans.
Psychopharmacology 2001;154(3):230-42.
2001: Silverman K; Svikis D; Robles E; Stitzer M L; Bigelow G E
A reinforcement-based therapeutic workplace for the treatment of drug abuse: six-month abstinence outcomes.
Experimental and clinical psychopharmacology 2001;9(1):14-23.
2001: Abreu M E; Bigelow G E; Fleisher L; Walsh S L
Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans.
Psychopharmacology 2001;154(1):76-84.
2001: Becker A B; Strain E C; Bigelow G E; Stitzer M L; Johnson R E
Gradual dose taper following chronic buprenorphine.
The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 2001;10(2):111-21.
2000: Johnson R E; Chutuape M A; Strain E C; Walsh S L; Stitzer M L; Bigelow G E
A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.
The New England journal of medicine 2000;343(18):1290-7.
2000: Preston K L; Bigelow G E
Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination.
The Journal of pharmacology and experimental therapeutics 2000;295(1):114-24.
2000: Walsh S L; Haberny K A; Bigelow G E
Modulation of intravenous cocaine effects by chronic oral cocaine in humans.
Psychopharmacology 2000;150(4):361-73.
2000: Strain E C; Stoller K; Walsh S L; Bigelow G E
Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.
Psychopharmacology 2000;148(4):374-83.
2000: Robles E; Silverman K; Preston K L; Cone E J; Katz E; Bigelow G E; Stitzer M L
The brief abstinence test: voucher-based reinforcement of cocaine abstinence.
Drug and alcohol dependence 2000;58(1-2):205-12.
1999: Silverman K; Chutuape M A; Bigelow G E; Stitzer M L
Voucher-based reinforcement of cocaine abstinence in treatment-resistant methadone patients: effects of reinforcement magnitude.
Psychopharmacology 1999;146(2):128-38.
1999: Jones H E; Bigelow G E; Preston K L
Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure.
The Journal of pharmacology and experimental therapeutics 1999;289(3):1350-61.
1999: Eissenberg T; Stitzer M L; Bigelow G E; Buchhalter A R; Walsh S L
Relative potency of levo-alpha-acetylmethadol and methadone in humans under acute dosing conditions.
The Journal of pharmacology and experimental therapeutics 1999;289(2):936-45.
1999: Strain E C; Bigelow G E; Liebson I A; Stitzer M L
Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial.
JAMA : the journal of the American Medical Association 1999;281(11):1000-5.
1998: Preston K L; Bigelow G E
Opioid discrimination in humans: discriminative and subjective effects of progressively lower training dose.
Behavioural pharmacology 1998;9(7):533-43.
1998: Jones H E; Strain E C; Bigelow G E; Walsh S L; Stitzer M L; Eissenberg T; Johnson R E
Induction with levomethadyl acetate: safety and efficacy.
Archives of general psychiatry 1998;55(8):729-36.
1998: Houtsmuller E J; Walsh S L; Schuh K J; Johnson R E; Stitzer M L; Bigelow G E
Dose-response analysis of opioid cross-tolerance and withdrawal suppression during LAAM maintenance.
The Journal of pharmacology and experimental therapeutics 1998;285(2):387-96.
1998: Schlaepfer T E; Strain E C; Greenberg B D; Preston K L; Lancaster E; Bigelow G E; Barta P E; Pearlson G D
Site of opioid action in the human brain: mu and kappa agonists' subjective and cerebral blood flow effects.
The American journal of psychiatry 1998;155(4):470-3.
1998: Walsh S L; Johnson R E; Cone E J; Bigelow G E
Intravenous and oral l-alpha-acetylmethadol: pharmacodynamics and pharmacokinetics in humans.
The Journal of pharmacology and experimental therapeutics 1998;285(1):71-82.
1998: Bigelow G E; Brooner R K; Silverman K
Competing motivations: drug reinforcement vs non-drug reinforcement.
Journal of psychopharmacology (Oxford, England) 1998;12(1):8-14.
1997: Eissenberg T; Bigelow G E; Strain E C; Walsh S L; Brooner R K; Stitzer M L; Johnson R E
Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence. A randomized clinical trial.
JAMA : the journal of the American Medical Association 1997;277(24):1945-51.
1997: Eissenberg T; Johnson R E; Bigelow G E; Walsh S L; Liebson I A; Strain E C; Stitzer M L
Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients.
Drug and alcohol dependence 1997;45(1-2):81-91.
1997: Dykstra L A; Preston K L; Bigelow G E
Discriminative stimulus and subjective effects of opioids with mu and kappa activity: data from laboratory animals and human subjects.
Psychopharmacology 1997;130(1):14-27.
1997: Strain E C; Walsh S L; Preston K L; Liebson I A; Bigelow G E
The effects of buprenorphine in buprenorphine-maintained volunteers.
Psychopharmacology 1997;129(4):329-38.
1997: Brooner R K; King V L; Kidorf M; Schmidt C W; Bigelow G E
Psychiatric and substance use comorbidity among treatment-seeking opioid abusers.
Archives of general psychiatry 1997;54(1):71-80.
1996: Walsh S L; Sullivan J T; Preston K L; Garner J E; Bigelow G E
Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans.
The Journal of pharmacology and experimental therapeutics 1996;279(2):524-38.
1996: Strain E C; Preston K L; Liebson I A; Bigelow G E
Opioid antagonist effects of dezocine in opioid-dependent humans.
Clinical pharmacology and therapeutics 1996;60(2):206-17.
1996: Schuh K J; Walsh S L; Bigelow G E; Preston K L; Stitzer M L
Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans.
The Journal of pharmacology and experimental therapeutics 1996;278(2):836-46.
1996: Silverman K; Chutuape M A; Bigelow G E; Stitzer M L
Voucher-based reinforcement of attendance by unemployed methadone patients in a job skills training program.
Drug and alcohol dependence 1996;41(3):197-207.
1996: Strain E C; Stitzer M L; Liebson I A; Bigelow G E
Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.
Journal of clinical psychopharmacology 1996;16(1):58-67.
1996: Eissenberg T; Greenwald M K; Johnson R E; Liebson I A; Bigelow G E; Stitzer M L
Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
The Journal of pharmacology and experimental therapeutics 1996;276(2):449-59.
1996: Preston K L; Sullivan J T; Strain E C; Bigelow G E
Enhancement of cocaine's abuse liability in methadone maintenance patients.
Psychopharmacology 1996;123(1):15-25.
1995: Silverman K; Chutuape M A; Svikis D S; Bigelow G E; Stitzer M L
Incongruity between occupational interests and academic skills in drug abusing women.
Drug and alcohol dependence 1995;40(2):115-23.
1995: Johnson R E; Eissenberg T; Stitzer M L; Strain E C; Liebson I A; Bigelow G E
Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing.
Drug and alcohol dependence 1995;40(1):27-35.
1995: Johnson R E; Eissenberg T; Stitzer M L; Strain E C; Liebson I A; Bigelow G E
A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence.
Drug and alcohol dependence 1995;40(1):17-25.
1995: Kendall J C; Sherman M F; Bigelow G E
Psychiatric symptoms in polysubstance abusers: relationship to race, sex, and age.
Addictive behaviors 1995;20(5):685-90.
1995: Greenfield L; Bigelow G E; Brooner R K
Validity of intravenous drug abusers' self-reported changes in HIV high-risk drug use behaviors.
Drug and alcohol dependence 1995;39(2):91-8.
1995: Haberny K A; Walsh S L; Ginn D H; Wilkins J N; Garner J E; Setoda D; Bigelow G E
Absence of acute cocaine interactions with the MAO-B inhibitor selegiline.
Drug and alcohol dependence 1995;39(1):55-62.
1995: Walsh S L; Preston K L; Bigelow G E; Stitzer M L
Acute administration of buprenorphine in humans: partial agonist and blockade effects.
The Journal of pharmacology and experimental therapeutics 1995;274(1):361-72.
1995: Walsh S L; June H L; Schuh K J; Preston K L; Bigelow G E; Stitzer M L
Effects of buprenorphine and methadone in methadone-maintained subjects.
Psychopharmacology 1995;119(3):268-76.
1995: Kidorf M; Sherman M F; Johnson J G; Bigelow G E
Alcohol expectancies and changes in beer consumption of first-year college students.
Addictive behaviors 1995;20(2):225-31.
1995: Strain E C; Preston K L; Liebson I A; Bigelow G E
Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
The Journal of pharmacology and experimental therapeutics 1995;272(2):628-38.
1994: Walsh S L; Preston K L; Sullivan J T; Fromme R; Bigelow G E
Fluoxetine alters the effects of intravenous cocaine in humans.
Journal of clinical psychopharmacology 1994;14(6):396-407.
1994: Strain E C; Stitzer M L; Liebson I A; Bigelow G E
Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users.
Psychopharmacology 1994;116(4):401-6.
1994: Preston K L; Bigelow G E
Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure.
The Journal of pharmacology and experimental therapeutics 1994;271(1):48-60.
1994: Strain E C; Stitzer M L; Liebson I A; Bigelow G E
Comparison of buprenorphine and methadone in the treatment of opioid dependence.
The American journal of psychiatry 1994;151(7):1025-30.
1994: King V L; Brooner R K; Bigelow G E; Schmidt C W; Felch L J; Gazaway P M
Condom use rates for specific sexual behaviors among opioid abusers entering treatment.
Drug and alcohol dependence 1994;35(3):231-8.
1994: Strain E C; Stitzer M L; Liebson I A; Bigelow G E
Outcome after methadone treatment: influence of prior treatment factors and current treatment status.
Drug and alcohol dependence 1994;35(3):223-30.
1994: Walsh S L; Preston K L; Stitzer M L; Cone E J; Bigelow G E
Clinical pharmacology of buprenorphine: ceiling effects at high doses.
Clinical pharmacology and therapeutics 1994;55(5):569-80.
1994: Walsh S L; Gilson S F; Jasinski D R; Stapleton J M; Phillips R L; Dannals R F; Schmidt J; Preston K L; Grayson R; Bigelow G E
Buprenorphine reduces cerebral glucose metabolism in polydrug abusers.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1994;10(3):157-70.
1994: Umbricht-Schneiter A; Ginn D H; Pabst K M; Bigelow G E
Providing medical care to methadone clinic patients: referral vs on-site care.
American journal of public health 1994;84(2):207-10.
1994: Rousar E; Brooner R K; Regier M W; Bigelow G E
Psychiatric distress in antisocial drug abusers: relation to other personality disorders.
Drug and alcohol dependence 1994;34(2):149-54.
1993: Strain E C; Preston K L; Liebson I A; Bigelow G E
Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
The Journal of pharmacology and experimental therapeutics 1993;267(2):624-34.
1993: Preston K L; Sullivan J T; Berger P; Bigelow G E
Effects of cocaine alone and in combination with mazindol in human cocaine abusers.
The Journal of pharmacology and experimental therapeutics 1993;267(1):296-307.
1993: Strain E C; Stitzer M L; Liebson I A; Bigelow G E
Methadone dose and treatment outcome.
Drug and alcohol dependence 1993;33(2):105-17.
1993: Strain E C; Buccino D L; Brooner R K; Schmidt C W; Bigelow G E
The triply diagnosed: patients with major mental illness, cognitive impairment, and substance abuse.
The Journal of nervous and mental disease 1993;181(9):585-7.
1993: Strain E C; Stitzer M L; Liebson I A; Bigelow G E
Dose-response effects of methadone in the treatment of opioid dependence.
Annals of internal medicine 1993;119(1):23-7.
1993: Brooner R K; Herbst J H; Schmidt C W; Bigelow G E; Costa P T
Antisocial personality disorder among drug abusers. Relations to other personality diagnoses and the five-factor model of personality.
The Journal of nervous and mental disease 1993;181(5):313-9.
1993: Preston K L; Bigelow G E
Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers.
The Journal of pharmacology and experimental therapeutics 1993;264(2):813-23.
1993: Weinhold L L; Bigelow G E
Opioid miosis: effects of lighting intensity and monocular and binocular exposure.
Drug and alcohol dependence 1993;31(2):177-81.
1993: Brooner R K; Greenfield L; Schmidt C W; Bigelow G E
Antisocial personality disorder and HIV infection among intravenous drug abusers.
The American journal of psychiatry 1993;150(1):53-8.
1993: Stitzer M L; Iguchi M Y; Kidorf M; Bigelow G E
Contingency management in methadone treatment: the case for positive incentives.
NIDA research monograph 1993;137():19-36.
1992: Weinhold L L; Preston K L; Farre M; Liebson I A; Bigelow G E
Buprenorphine alone and in combination with naloxone in non-dependent humans.
Drug and alcohol dependence 1992;30(3):263-74.
1992: Preston K L; Sullivan J T; Strain E C; Bigelow G E
Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers.
The Journal of pharmacology and experimental therapeutics 1992;262(1):279-91.
1992: Strain E C; Preston K L; Liebson I A; Bigelow G E
Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.
The Journal of pharmacology and experimental therapeutics 1992;261(3):985-93.
1992: Brooner R K; Schmidt C W; Felch L J; Bigelow G E
Antisocial behavior of intravenous drug abusers: implications for diagnosis of antisocial personality disorder.
The American journal of psychiatry 1992;149(4):482-7.
1992: Preston K L; Liebson I A; Bigelow G E
Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination.
The Journal of pharmacology and experimental therapeutics 1992;261(1):62-71.
1992: Sherman M F; Bigelow G E
Validity of patients' self-reported drug use as a function of treatment status.
Drug and alcohol dependence 1992;30(1):1-11.
1992: Greenfield L; Bigelow G E; Brooner R K
HIV risk behavior in drug users: increased blood "booting" during cocaine injection.
AIDS education and prevention : official publication of the International Society for AIDS Education 1992;4(2):95-107.
1992: Bigelow G E; Preston K L
Assessment of buprenorphine in a drug discrimination procedure in humans.
NIDA research monograph 1992;121():28-37.
1991: Bigelow G E
Human drug abuse liability assessment: opioids and analgesics.
British journal of addiction 1991;86(12):1615-23.
1991: Stitzer M L; Wright C; Bigelow G E; June H L; Felch L J
Time course of naloxone-precipitated withdrawal after acute methadone exposure in humans.
Drug and alcohol dependence 1991;29(1):39-46.
1991: McCaul M E; Turkkan J S; Svikis D S; Bigelow G E
Familial density of alcoholism: effects on psychophysiological responses to ethanol.
Alcohol (Fayetteville, N.Y.) 1991;8(3):219-22.
1991: Strain E C; Stitzer M L; Bigelow G E
Early treatment time course of depressive symptoms in opiate addicts.
The Journal of nervous and mental disease 1991;179(4):215-21.
1991: Strain E C; Brooner R K; Bigelow G E
Clustering of multiple substance use and psychiatric diagnoses in opiate addicts.
Drug and alcohol dependence 1991;27(2):127-34.
1991: Preston K L; Funderburk F R; Liebson I A; Bigelow G E
Evaluation of the abuse potential of the novel analgesic flupirtine maleate.
Drug and alcohol dependence 1991;27(2):101-13.
1991: Wright C; Bigelow G E; Stitzer M L; Liebson I A
Acute physical dependence in humans: repeated naloxone-precipitated withdrawal after a single dose of methadone.
Drug and alcohol dependence 1991;27(2):139-48.
1991: McCaul M E; Turkkan J S; Svikis D S; Bigelow G E
Alcohol and secobarbital effects as a function of familial alcoholism: extended intoxication and increased withdrawal effects.
Alcoholism, clinical and experimental research 1991;15(1):94-101.
1990: Preston K L; Bigelow G E; Liebson I A
Discrimination of butorphanol and nalbuphine in opioid-dependent humans.
Pharmacology, biochemistry, and behavior 1990;37(3):511-22.
1990: McCaul M E; Turkkan J S; Svikis D S; Bigelow G E
Alcohol and secobarbital effects as a function of familial alcoholism: acute psychophysiological effects.
Alcoholism, clinical and experimental research 1990;14(5):704-12.
1990: Brooner R K; Bigelow G E; Strain E; Schmidt C W
Intravenous drug abusers with antisocial personality disorder: increased HIV risk behavior.
Drug and alcohol dependence 1990;26(1):39-44.
1990: McCaul M E; Turkkan J S; Svikis D S; Bigelow G E; Cromwell C C
Alcohol and drug use by college males as a function of family alcoholism history.
Alcoholism, clinical and experimental research 1990;14(3):467-71.
1990: Heishman S J; Stitzer M L; Bigelow G E; Liebson I A
Acute opioid physical dependence in humans: effect of naloxone at 6 and 24 hours postmorphine.
Pharmacology, biochemistry, and behavior 1990;36(2):393-9.
1990: Preston K L; Bigelow G E; Liebson I A
Effects of sublingually given naloxone in opioid-dependent human volunteers.
Drug and alcohol dependence 1990;25(1):27-34.
1990: McCaul M E; Turkkan J S; Svikis D S; Bigelow G E
Acute effects of secobarbital and ethanol as a function of family alcoholism history.
NIDA research monograph 1990;105():534.
1990: Preston K L; Sullivan J T; Strain E C; Bigelow G E
Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers.
NIDA research monograph 1990;105():507.
1990: Brooner R K; Bigelow G E; Greenfield L; Strain E C; Schmidt C W
Intravenous drug abusers with antisocial personality disorder: high rate of HIV-1 infection.
NIDA research monograph 1990;105():488-9.
1990: Weinhold L L; Bigelow G E
Factors influencing assessment of opioid miosis in humans.
NIDA research monograph 1990;105():419-20.
1990: Strain E C; Bigelow G E; Preston K L; Liebson I
The effects of buprenorphine in methadone-dependent volunteers.
NIDA research monograph 1990;105():584.
1989: Bickel W K; Bigelow G E; Preston K L; Liebson I A
Opioid drug discrimination in humans: stability, specificity and relation to self-reported drug effect.
The Journal of pharmacology and experimental therapeutics 1989;251(3):1053-63.
1989: Griffiths R R; Bigelow G E; Liebson I A
Reinforcing effects of caffeine in coffee and capsules.
Journal of the experimental analysis of behavior 1989;52(2):127-40.
1989: Heishman S J; Stitzer M L; Bigelow G E; Liebson I A
Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval. I.
The Journal of pharmacology and experimental therapeutics 1989;250(2):485-91.
1989: Preston K L; Bigelow G E; Bickel W K; Liebson I A
Drug discrimination in human postaddicts: agonist-antagonist opioids.
The Journal of pharmacology and experimental therapeutics 1989;250(1):184-96.
1989: Preston K L; Bigelow G E; Liebson I A
Antagonist effects of nalbuphine in opioid-dependent human volunteers.
The Journal of pharmacology and experimental therapeutics 1989;248(3):929-37.
1989: Heishman S J; Stitzer M L; Bigelow G E; Liebson I A
Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure.
The Journal of pharmacology and experimental therapeutics 1989;248(1):127-34.
1989: Rand C S; Stitzer M L; Bigelow G E; Mead A M
The effects of contingent payment and frequent workplace monitoring on smoking abstinence.
Addictive behaviors 1989;14(2):121-8.
1989: Wright C; Bigelow G E; Stitzer M L
Acute physical dependence in man: repeated naloxone-precipitated withdrawal after a single dose of methadone.
NIDA research monograph 1989;95():395-6.
1989: Weinhold L L; Bigelow G E; Preston K L
Combination of naloxone with buprenorphine in humans.
NIDA research monograph 1989;95():485.
1989: Brooner R K; Bigelow G E; Regier M W
Methadone maintenance: high rate of other substance use disorders and relationship to psychiatric comorbidity.
NIDA research monograph 1989;95():442.
1989: McCaul M E; Svikis D S; Turkkan J S; Bigelow G E; Cromwell C C
Degree of familial alcoholism: effects on substance use by college males.
NIDA research monograph 1989;95():372-3.
1989: Bigelow G E; Preston K L
Drug discrimination: methods for drug characterization and classification.
NIDA research monograph 1989;92():101-22.
1988: Funderburk F R; Griffiths R R; McLeod D R; Bigelow G E; Mackenzie A; Liebson I A; Nemeth-Coslett R
Relative abuse liability of lorazepam and diazepam: an evaluation in 'recreational' drug users.
Drug and alcohol dependence 1988;22(3):215-22.
1988: Heishman S J; Stitzer M L; Bigelow G E
Alcohol and marijuana: comparative dose effect profiles in humans.
Pharmacology, biochemistry, and behavior 1988;31(3):649-55.
1988: Iguchi M Y; Stitzer M L; Bigelow G E; Liebson I A
Contingency management in methadone maintenance: effects of reinforcing and aversive consequences on illicit polydrug use.
Drug and alcohol dependence 1988;22(1-2):1-7.
1988: Bickel W K; Stitzer M L; Bigelow G E; Liebson I A; Jasinski D R; Johnson R E
Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
The Journal of pharmacology and experimental therapeutics 1988;247(1):47-53.
1988: Preston K L; Bigelow G E; Liebson I A
Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.
The Journal of pharmacology and experimental therapeutics 1988;246(2):441-8.
1988: Bickel W K; Stitzer M L; Liebson I A; Bigelow G E
Acute physical dependence in man: effects of naloxone after brief morphine exposure.
The Journal of pharmacology and experimental therapeutics 1988;244(1):126-32.
1988: Bickel W K; Stitzer M L; Bigelow G E; Liebson I A; Jasinski D R; Johnson R E
A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts.
Clinical pharmacology and therapeutics 1988;43(1):72-8.
1988: Bigelow G E; Brooner R K; McCaul M E; Svikis D S
Biological vulnerability: treatment implications/applications.
NIDA research monograph 1988;89():165-73.
1988: Preston K; Bigelow G; Bickel W; Liebson I
Drug discrimination in human post-addicts: agonist/antagonist opioids.
NIDA research monograph 1988;81():209-15.
1988: Preston K L; Bigelow G E; Liebson I A
Buprenorphine and naloxone alone and in combination in opioid-dependent humans.
Psychopharmacology 1988;94(4):484-90.
1987: Preston K L; Bigelow G E; Bickel W; Liebson I A
Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline.
The Journal of pharmacology and experimental therapeutics 1987;243(3):1002-9.
1987: Liebson I; Bigelow G; Griffiths R R; Funderburk F R
Phenylpropanolamine: effects on subjective and cardiovascular variables at recommended over-the-counter dose levels.
Journal of clinical pharmacology 1987;27(9):685-93.
1987: Preston K L; Bigelow G E; Liebson I A
Comparative evaluation of morphine, pentazocine and ciramadol in postaddicts.
The Journal of pharmacology and experimental therapeutics 1987;240(3):900-10.
1987: Stitzer M L; Bickel W K; Bigelow G E
Altered dose incentive procedures: effects on polydrug use among methadone maintenance patients.
NIDA research monograph 1987;76():162-7.
1987: Bickel W K; Johnson R E; Stitzer M L; Bigelow G E; Liebson I A; Jasinski D R
A clinical trial of buprenorphine: I. Comparison with methadone in the detoxification of heroin addicts. II. Examination of its opioid blocking properties.
NIDA research monograph 1987;76():182-8.
1987: Preston K L; Bigelow G E; Liebson I A
Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.
NIDA research monograph 1987;76():157-61.
1987: Bigelow G E; Preston K L; Liebson I A
Abuse liability assessment of buprenorphine-naloxone combinations.
NIDA research monograph 1987;76():145-9.
1986: Stitzer M L; Bickel W K; Bigelow G E; Liebson I A
Effect of methadone dose contingencies on urinalysis test results of polydrug-abusing methadone-maintenance patients.
Drug and alcohol dependence 1986;18(4):341-8.
1986: Griffiths R R; Bigelow G E; Liebson I A
Human coffee drinking: reinforcing and physical dependence producing effects of caffeine.
The Journal of pharmacology and experimental therapeutics 1986;239(2):416-25.
1986: Higgins S T; Stitzer M L; Bigelow G E; Liebson I A
Contingent methadone delivery: effects on illicit-opiate use.
Drug and alcohol dependence 1986;17(4):311-22.
1986: Griffiths R R; Bigelow G E; Liebson I A; O'Keeffe M; O'Leary D; Russ N
Human coffee drinking: manipulation of concentration and caffeine dose.
Journal of the experimental analysis of behavior 1986;45(2):133-48.
1986: Stitzer M L; Rand C S; Bigelow G E; Mead A M
Contingent payment procedures for smoking reduction and cessation.
Journal of applied behavior analysis 1986;19(2):197-202.
1986: Ossip-Klein D J; Bigelow G; Parker S R; Curry S; Hall S; Kirkland S
Classification and assessment of smoking behavior.
Health psychology : official journal of the Division of Health Psychology, American Psychological Association 1986;5 Suppl():3-11.
1986: Bigelow G E; Rand C S; Gross J; Burling T A; Gottlieb S H
Smoking cessation and relapse among cardiac patients.
NIDA research monograph 1986;72():167-71.
1986: Griffiths R R; Brady J V; Ator N A; Lamb R; Bigelow G E; Roache J D
Progress report from the Division of Behavioral Biology, the Johns Hopkins University School of Medicine.
NIDA research monograph 1986;67():93-7.
1986: Bickel W K; Preston K L; Bigelow G E; Liebson I A
Three-way drug discrimination in post-addict volunteers: hydromorphone, pentazocine, and saline.
NIDA research monograph 1986;67():177-83.
1985: Preston K L; Bigelow G E; Liebson I A
Self-administration of clonidine, oxazepam, and hydromorphone by patients undergoing methadone detoxification.
Clinical pharmacology and therapeutics 1985;38(2):219-27.
1985: Preston K L; Bigelow G E
Pharmacological advances in addiction treatment.
The International journal of the addictions 1985;20(6-7):845-67.
1985: Higgins S T; Stitzer M L; McCaul M E; Bigelow G E; Liebson I A
Pupillary response to methadone challenge in heroin users.
Clinical pharmacology and therapeutics 1985;37(4):460-3.
1985: Stitzer M L; Bigelow G E
Contingent reinforcement for reduced breath carbon monoxide levels: target-specific effects on cigarette smoking.
Addictive behaviors 1985;10(4):345-9.
1985: Burling T A; Stitzer M L; Bigelow G E; Mead A M
Smoking topography and carbon monoxide levels in smokers.
Addictive behaviors 1985;10(3):319-23.
1985: Stitzer M L; Bigelow G E; McCaul M E
Behavior therapy in drug abuse treatment: review and evaluation.
NIDA research monograph 1985;58():31-50.
1984: Preston K L; Griffiths R R; Stitzer M L; Bigelow G E; Liebson I A
Diazepam and methadone interactions in methadone maintenance.
Clinical pharmacology and therapeutics 1984;36(4):534-41.
1984: Stitzer M L; McCaul M E; Bigelow G E; Liebson I A
Chronic opiate use during methadone detoxification: effects of a dose increase treatment.
Drug and alcohol dependence 1984;14(1):37-44.
1984: Stitzer M L; Bigelow G E; Liebson I A
Single-day methadone dose alteration: detectability and symptoms.
Clinical pharmacology and therapeutics 1984;36(2):244-50.
1984: Stitzer M L; Bigelow G E
Contingent methadone take-home privileges: effects on compliance with fee payment schedules.
Drug and alcohol dependence 1984;13(4):395-9.
1984: Griffiths R R; McLeod D R; Bigelow G E; Liebson I A; Roache J D; Nowowieski P
Comparison of diazepam and oxazepam: preference, liking and extent of abuse.
The Journal of pharmacology and experimental therapeutics 1984;229(2):501-8.
1984: McCaul M E; Stitzer M L; Bigelow G E; Liebson I A
Methadone detoxification: effects of methadone dose versus time in treatment.
NIDA research monograph 1984;49():269-74.
1984: Stitzer M L; McCaul M E; Bigelow G E; Liebson I A
Comparison of a behavioral and a pharmacological treatment for reduction of illicit opiate use.
NIDA research monograph 1984;49():255-61.
1984: Preston K L; Bigelow G E; Liebson I A
Self-administration of clonidine and oxazepam by methadone detoxification patients.
NIDA research monograph 1984;49():192-8.
1984: Brady J V; Griffiths R R; Hienz R D; Bigelow G E; Emurian H H; Lukas S E; Ator N A; Nellis M J; Ray R L; Pearlson G D
Abuse liability and behavioral toxicity assessment: progress report from the behavioral biology laboratories of the Johns Hopkins University School of Medicine.
NIDA research monograph 1984;49():92-108.
1984: McCaul M E; Stitzer M L; Bigelow G E; Liebson I A
Contingency management interventions: effects on treatment outcome during methadone detoxification.
Journal of applied behavior analysis 1984;17(1):35-43.
1984: Stitzer M L; Bigelow G E
Contingent reinforcement for carbon monoxide reduction: within-subject effects of pay amount.
Journal of applied behavior analysis 1984;17(4):477-83.
1984: Singleton E G; Sherman M F; Bigelow G E
The index of choice: indications of methadone patients' selection of naltrexone treatment.
The American journal of drug and alcohol abuse 1984;10(2):209-21.
1984: Griffiths R R; Bigelow G E; Liebson I A; Roache J D
Dose effect and preference comparison of diazepam and oxazepam.
NIDA research monograph 1984;55():97-8.
1984: Stitzer M L; McCaul M E; Bigelow G E; Liebson I A
Effects of a dose increase on chronic opiate use during methadone detoxification.
NIDA research monograph 1984;55():197-201.
1984: McCaul M E; Stitzer M L; Bigelow G E; Liebson I A
Outpatient methadone detoxification: effects of diazepam and doxepin as adjunct medications.
NIDA research monograph 1984;55():191-6.
1984: Higgins S T; Stitzer M L; Bigelow G E; Liebson I A
Contingent methadone dose increases as a method for reducing illicit opiate use in detoxification patients.
NIDA research monograph 1984;55():178-84.
1984: Griffiths R R; McLeod D R; Bigelow G E; Liebson I A; Roache J D
Relative abuse liability of diazepam and oxazepam: behavioral and subjective dose effects.
Psychopharmacology 1984;84(2):147-54.
1984: Bigelow G E; Stitzer M L; Liebson I A
The role of behavioral contingency management in drug abuse treatment.
NIDA research monograph 1984;46():36-52.
1984: Burling T A; Singleton E G; Bigelow G E; Baile W F; Gottlieb S H
Smoking following myocardial infarction: a critical review of the literature.
Health psychology : official journal of the Division of Health Psychology, American Psychological Association 1984;3(1):83-96.
1984: Bigelow G E; Brady J V; Griffiths R R; Stitzer M L; Ator N A; Higgins S T; Liebson I A; Lucas S E
Progress report from the Division of Behavioral Biology, the Johns Hopkins University School of Medicine.
NIDA research monograph 1984;55():66-75.
1984: Stitzer M L; Bigelow G E; Liebson I A; McCaul M E
Contingency management of supplemental drug use during methadone maintenance treatment.
NIDA research monograph 1984;46():84-103.
1984: Preston K L; Bigelow G E; Stitzer M L; Liebson I A
Three-choice discrimination in methadone maintenance patients: hydromorphone, naloxone, and saline.
NIDA research monograph 1984;55():151-7.
1983: Stitzer M L; McCaul M E; Bigelow G E; Liebson I
Treatment outcome in methadone detoxification: relationship to initial levels of illicit opiate use.
Drug and alcohol dependence 1983;12(3):259-67.
1983: Griffiths R R; Bigelow G E; Liebson I
Differential effects of diazepam and pentobarbital on mood and behavior.
Archives of general psychiatry 1983;40(8):865-73.
1983: Stitzer M L; McCaul M E; Bigelow G E; Liebson I A
Oral methadone self-administration: effects of dose and alternative reinforcers.
Clinical pharmacology and therapeutics 1983;34(1):29-35.
1983: McCaul M E; Stitzer M L; Bigelow G E; Liebson I A
Initial opiate use and treatment outcome in methadone detoxification patients.
NIDA research monograph 1983;43():280-6.
1983: Bigelow G E; Griffiths R R; Stitzer M L; Liebson I A
Development of clinical procedures for abuse liability assessment: progress report from the Behavioral Pharmacology Research Unit of the Johns Hopkins University School of Medicine and Baltimore City Hospitals.
NIDA research monograph 1983;43():125-31.
1983: McCaul M E; Stitzer M L; Bigelow G E; Liebson I A
Intravenous hydromorphone: effects in opiate-free and methadone maintenance subjects.
NIDA research monograph 1983;43():238-44.
1982: Falk J L; Schuster C R; Bigelow G E; Woods J H
Progress and needs in the experimental analysis of drug and alcohol dependence.
The American psychologist 1982;37(10):1124-7.
1982: McCaul M E; Bigelow G E; Stitzer M L; Liebson I
Short-term effects of oral methadone in methadone maintenance subjects.
Clinical pharmacology and therapeutics 1982;31(6):753-61.
1982: Stitzer M; Bigelow G; Liebson I
Contingent reinforcement of benzodiazepine-free urines from methadone maintenance patients.
NIDA research monograph 1982;41():282-7.
1982: Stitzer M L; Bigelow G E; Liebson I A
Comparison of three outpatient methadone detoxification procedures.
NIDA research monograph 1982;41():239-45.
1982: McLeod D R; Bigelow G E; Liebson I A
Self-regulated opioid detoxification by humans: effects of methadone pretreatment.
NIDA research monograph 1982;41():232-8.
1982: McCaul M; Stitzer M; Bigelow G; Liebson I
Physiological and subjective effects of hydromorphone in postaddict volunteers.
NIDA research monograph 1982;41():301-8.
1982: Griffiths R R; Henningfield J E; Bigelow G E
Human cigarette smoking: manipulation of number of puffs per bout, interbout interval and nicotine dose.
The Journal of pharmacology and experimental therapeutics 1982;220(2):256-65.
1982: Stitzer M L; Bigelow G E
Contingent reinforcement for reduced carbon monoxide levels in cigarette smokers.
Addictive behaviors 1982;7(4):403-12.
1982: Burling T A; Stitzer M L; Bigelow G E; Russ N W
Techniques used by smokers during contingency motivated smoking reduction.
Addictive behaviors 1982;7(4):397-401.
1982: Baile W F; Bigelow G E; Gottlieb S H; Stitzer M L; Sacktor J D
Rapid resumption of cigarette smoking following myocardial infarction: inverse relation to MI severity.
Addictive behaviors 1982;7(4):373-80.
1982: Stitzer M L; Bigelow G E; Liebson I A; Hawthorne J W
Contingent reinforcement for benzodiazepine-free urines: evaluation of a drug abuse treatment intervention.
Journal of applied behavior analysis 1982;15(4):493-503.
1981: Griffiths R R; Brady J V; Bigelow G E
Predicting the dependence liability of stimulant drugs.
NIDA research monograph 1981;37():182-96.
1981: Stitzer M L; Griffiths R R; Bigelow G E; Liebson I A
Social stimulus factors in drug effects in human subjects.
NIDA research monograph 1981;37():130-54.
1981: Stitzer M L; Griffiths R R; Bigelow G E; Liebson I
Human social conversation: effects of ethanol, secobarbital and chlorpromazine.
Pharmacology, biochemistry, and behavior 1981;14(3):353-60.
1981: Griffiths R R; Bigelow G E; Liebson I
Human preference comparison of pentobarbital, diazepam, and placebo.
NIDA research monograph 1981;34():220-5.
1981: Bigelow G E; Stitzer M L; Griffiths R R; Liebson I A
Contingency management approaches to drug self-administration and drug abuse: efficacy and limitations.
Addictive behaviors 1981;6(3):241-52.
1980: Griffiths R R; Bigelow G E; Liebson I; Kaliszak J E
Drug preference in humans: double-blind choice comparison of pentobarbital, diazepam and placebo.
The Journal of pharmacology and experimental therapeutics 1980;215(3):649-61.
1980: Bigelow G E; Griffiths R R; Liebson I; Kaliszak J E
Double-blind evaluation of reinforcing and anorectic actions of weight control medications. Interaction of pharmacological and behavioral treatments.
Archives of general psychiatry 1980;37(10):1118-23.
1980: Bigelow G; Stitzer M; Lawrence C; Krasnegor N; D'Lugoff B; Hawthorne J
Narcotics addiction treatment: behavioral methods concurrent with methadone maintenance.
The International journal of the addictions 1980;15(3):427-37.
1980: Stitzer M L; Bigelow G E; Liebson I
Reducing drug use among methadone maintenance clients: contingent reinforcement for morphine-free urines.
Addictive behaviors 1980;5(4):333-40.
1979: Griffiths R R; Bigelow G; Liebson I
Human drug self-administration: double-blind comparison of pentobarbital, diazepam, chlorpromazine and placebo.
The Journal of pharmacology and experimental therapeutics 1979;210(2):301-10.
1979: Stitzer M L; Bigelow G E; Liebson I
Reinforcement of drug abstinence: a behavioral approach to drug abuse treatment.
NIDA research monograph 1979;(25):68-90.
1979: Robichaud C; Strickler D; Bigelow G; Liebson I
Disulfiram maintenance employee alcoholism treatment: a three-phase evaluation.
Behaviour research and therapy 1979;17(6):618-21.
1979: Stitzer M L; Bigelow G E; Liebson I
Reducing benzodiazepine self-administration with contingent reinforcement.
Addictive behaviors 1979;4(3):245-52.
1979: Stitzer M; Bigelow G; Liebson I
Supplementary methadone self administration among methadone maintenance clients.
Addictive behaviors 1979;4(1):61-6.
1978: Liebson I A; Tommasello A; Bigelow G E
A behavioral treatment of alcoholic methadone patients.
Annals of internal medicine 1978;89(3):342-4.
1978: Stitzer M; Bigelow G
Contingency management in a methadone maintenance program: availability of reinforcers.
The International journal of the addictions 1978;13(5):737-46.
1978: Bigelow G E; Liebson I; Kaliszak J; Griffiths R R
Therapeutic self-medication as a context for drug abuse research.
NIDA research monograph 1978;(20):44-58.
1978: Griffiths R R; Bigelow G E; Liebson I
Experimental drug self-administration: generality across species and type of drug.
NIDA research monograph 1978;(20):24-43.
1978: Stitzer M; Bigelow G E
Drug abuse research in outpatient clinics.
NIDA research monograph 1978;(20):59-67.
1977: Griffiths R R; Stitzer M; Corker K; Bigelow G; Liebson I
Drug-produced changes in human social behavior: facilitation by d-amphetamine.
Pharmacology, biochemistry, and behavior 1977;7(4):365-72.
1977: Griffiths R R; Bigelow G; Liebson I
Comparison of social time-out and activity time-out procedures in supressing ethanol self-administration in alcoholics.
Behaviour research and therapy 1977;15(4):329-36.
1977: Stitzer M; Bigelow G; Lawrence C; Cohen J; D'Lugoff B; Hawthorne J
Medication take-home as a reinforcer in a methadone maintenance program.
Addictive behaviors 1977;2(1):9-14.
1977: Bigelow G E; Griffiths R R; Liebson I A
Pharmacological influences upon human ethanol self-administration.
Advances in experimental medicine and biology 1977;85B():523-38.
1977: Strickler D; Bigelow G; Wells D; Liebson I
Effects of relaxation instructions on the electromyographic responses of abstinent alcoholics to drinking-related stimuli.
Behaviour research and therapy 1977;15(6):500-2.
1976: Bigelow G E; Griffiths R R; Liebson I A
Effects of response requirement upon human sedative self-administration and drug-seeking behavior.
Pharmacology, biochemistry, and behavior 1976;5(6):681-5.
1976: Griffiths R R; Bigelow G E; Liebson I
Human sedative self-administration: effects of interingestion interval and dose.
The Journal of pharmacology and experimental therapeutics 1976;197(3):488-94.
1976: Griffiths R R; Bigelow G E; Liebson I
Facilitation of human tobacco self-administration by ethanol: a behavioral analysis.
Journal of the experimental analysis of behavior 1976;25(3):279-92.
1976: Bigelow G; Strickler D; Liebson I; Griffiths R
Maintaining disulfiram ingestion among outpatient alcoholics: a security-deposit contingency contracting procedure.
Behaviour research and therapy 1976;14(5):378-81.
1976: Strickler D; Bigelow G; Lawrence C; Liebson I
Moderate drinking as an alternative to alcohol abuse: a non-aversive procedure.
Behaviour research and therapy 1976;14(4):279-83.
1975: Bigelow G; Griffiths R; Liebson I
Experimental human drug self-administration: methodology and application to the study of sedative abuse.
Pharmacological reviews 1975;27(4):523-31.
1975: Bigelow G; Griffiths R; Liebson I
Experimental models for the modification of human drug self-administration: Methodological developments in the study of ethanol self-administration by alcoholics.
Federation proceedings 1975;34(9):1785-92.
1975: Griffiths R; Bigelow G; Liebson I
Effect of ethanol self-administration on choice behavior: money vs. socializing.
Pharmacology, biochemistry, and behavior 1975;3(3):443-6.
1974: Griffiths R; Bigelow G; Liebson I
Suppression of ethanol self-administration in alcoholics by contingent time-out from social interactions.
Behaviour research and therapy 1974;12(4):327-34.
1974: Bigelow G; Liebson I; Griffiths H
Alcoholic drinking: suppression by a brief time-out procedure.
Behaviour research and therapy 1974;12(2):107-15.
1974: Griffiths R; Bigelow G; Liebson I
Assessment of effects of ethanol self-administration on social interactions in alcoholics.
Psychopharmacologia 1974;38(2):105-10.
1973: Pickens R; Bigelow G; Griffiths R
An experimental approach to treating chronic alcoholism: a case study and one-year follow-up.
Behaviour research and therapy 1973;11(3):321-5.
1973: Liebson I; Bigelow G; Flamer R
Alcoholism among methadone patients: a specific treatment method.
The American journal of psychiatry 1973;130(4):483-5.
1972: Liebson I; Bigelow G
A behavioural-pharmacological treatment of dually addicted patients.
Behaviour research and therapy 1972;10(4):403-5.
1972: Bigelow G; Cohen M; Liebson I; Faillace L A
Abstinence or moderation? Choice by alcoholics.
Behaviour research and therapy 1972;10(3):209-14.

Sign-in to see more